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Serum levels of pepsinogen and gastrin are parameters that can be used as biomarkers for gastric mucosa. The aim of this study was to
validate these serum biomarkers, that is pepsinogen A (PGA), pepsinogen C (PGC), PGA/PGC ratio, and gastrin, as screening tests for
precancerous lesions: atrophic chronic gastritis (ACG) or Helicobacter pylori-related corpus-predominant or multifocal atrophy. The study
population was comprised of a subsample of 284 patients from the 451 included in the Eurohepygast cohort, between 1995 and 1997.
The concentrations of PGA, PGC, and gastrin were measured by radioimmunoassays. Histological diagnosis was the gold standard. Cut-off
points were calculated using receiving operator characteristics (ROC) curves. Factors linked to variation of biomarkers were identified
using multivariate linear regression. The mean of each biomarker in the sample was: PGA, 77.4mgl
 1;P G C ,1 3 . 2mgl
 1; PGA/PGC, 6.7;
and gastrin, 62.4ngl
 1. For ACG patients, the areas under the PGA, PGC, PGA/PGC, and gastrin ROC curves were 0.55, 0.62, 0.73, and
0.58, respectively. The best cut-off point for PGA/PGC was 5.6, with sensitivity 65% and specificity 77.9%. For H. pylori-related corpus-
predominant or multifocal atrophy, the areas under the respective ROC curves were 0.57, 0.67, 0.84, and 0.69. The best cut-off point for
PGA/PGC was 4.7, with sensitivity 77.1% and specificity 87.4%. The results suggested that only the PGA/PGC ratio can be considered as a
biomarker for precancerous lesions of the stomach, and may be useful as a screening test.
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A number of studies pointed out the importance of atrophic
chronic gastritis (ACG) in the evolution of chronic gastritis
towards intestinal-type gastric adenocarcinoma (Correa et al, 1975,
1990a).
The prevalence of ACG in the general population is still difficult
to evaluate, since most of the data currently available were
obtained from endoscopic studies of patients with digestive
complaints. Only a few major studies have been conducted in
the Finnish (Ihama ¨ki et al, 1978, 1985; Kekki et al, 1987) and in the
Columbian (Correa et al, 1990b) populations. The difficulty in
performing follow-up studies that would provide insight into risk
factors, natural history, or the impact of Helicobacter pylori
eradication on ACG arises from a lack of noninvasive tests, owing
to the need of endoscopies to obtain biopsies for histological
diagnosis.
Pepsinogen A (PGA) is secreted only by the chief cells of the
corpus, and its serum level decreases with increasing grade of the
corpus atrophy (loss of oxyntic glands) (Asaka et al, 1992). It is
also an indirect measure of the corpus mass. Pepsinogen C (PGC)
is secreted by antral glands, corpus chief cells, and the duodenal
bulb in large quantities, and therefore PGC is not a direct measure
of corpus atrophy (Plebani, 1993). Given that the majority of
previous studies were performed on patients with pernicious
anaemia or their relatives (Samloff et al, 1982; Borch et al, 1989),
or individuals from populations with a high risk of gastric
adenocarcinoma (Miki et al, 1987), that is subjects with severe
corpus atrophy, PGA was a more interesting marker than PGC.
Furthermore, the first studies that validated biomarkers used
serological techniques and histological classifications, which have
changed. In the present study, neither PGA nor PGC alone were
good markers, contrary to the PGA/PGC ratio. Indeed, H. pylori
infection normally progresses from the antrum to the corpus and,
consequently, atrophy is more common in the antrum or both the
antrum and the corpus than in the corpus alone (Sipponen et al,
1991).
In addition to epidemiological needs, there are three other main
reasons underlying the necessity of a practical, reliable, and
inexpensive noninvasive screening test: (a) the association between
ACG and intestinal-type gastric adenocarcinoma; (b) the prognosis
of surgical treatment of gastric adenocarcinoma, which depends on
the precocity of the detection of lesions (Craanen et al, 1991); and
(c) the screening for ACG in patients from high gastric risk groups
for gastric cancer, after eradication of H. pylori (El-Omar et al,
2000). The enzymes PGA and PGC and the hormone gastrin are
good candidates for such a test, and have been evaluated in several
countries. The characteristics of the tests varied widely between
studies, and consistently did not identify good strategies for
screening ACG (Borch et al, 1989; Kekki et al, 1991; Palli et al,
1991; Miki et al, 1995; Knight et al, 1996; Oksanen et al, 2000; Ley
et al, 2001).
Eurohepygast is a large European multicentre cohort, whose aim
is to study the natural history of chronic gastritis, and for whom a
large database is available (Eurohepygast Study Group, 2002).
Using these data at patients’ inclusion, the aim of the present
analysis was to evaluate the performance of the biomarkers PGA,
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trophic chronic gastritis (non-ACG) and ACG in this European
dyspeptic population who have consulted gastroenterologists.
PATIENTS AND METHODS
Sample
This cross-sectional study was based on data from the Euro-
hepygast cohort collected between 1995 and 1997 at the inclusion
of patients. A total of 451 patients were enrolled from 14 different
European countries. To be included, patients with dyspepsia had
to present themselves at one of the 19 participating European
centres, to be between 18 and 75 years of age, and to have received
no previous H. pylori eradication treatment nor proton pump
inhibitors. Endoscopy with biopsies was performed. A question-
naire was filled out by the clinician and a blood sample was taken
from nonfasting patients. Only a subsample of 284 patients was
included in this study (Figure 1).
Endoscopy
Four biopsies were taken from the mid-antrum, two for histology
and two for culture (Me ´graud et al, 1999). Four biopsies were taken
from the greater curvature of the mid-corpus, two for histology
and two for culture. Biopsies for histology were placed in 10%
formalin, and the remaining were immediately frozen at  801C.
Macroscopic findings were recorded according to the Sydney
classification system for endoscopy (Tytgat, 1991).
Histopathological diagnosis
For histological diagnoses, biopsies were routinely embedded in
paraffin blocks, then sectioned and stained in each local centre.
The stained slides were subsequently sent to a central laboratory,
and examined by a single gastrointestinal pathologist (PS). All
histopathological characteristics and parameters from the antrum
as well as the corpus were graded and classified as normal mucosa,
non-ACG, or ACG according to the initial and updated Sydney
System (Price, 1991; Dixon et al, 1996). Normal mucosa or non-
ACG was defined by the absence of any form of antral atrophy and
no lesion in the corpus. ACG was defined as any form of moderate
or severe atrophy with or without intestinal metaplasia and
associated with chronic inflammation. H. pylori-related corpus-
predominant atrophy was classified in ACG as well as multifocal
ACG.
H. pylori-related corpus-predominant or corpus-limited
atrophic gastritis is an existing topographic type of chronic
gastritis (Correa, 1989). In this type, the morphology of the antral
and corpus biopsies resembles that of the autoimmune atrophic
gastritis: atrophy of advanced grade is seen predominantly or only
in the corpus biopsies. Instead, or in the coassociation with
autoimmune phenomena, there is evidence (usually increased
antibody titres) of an ongoing H. pylori infection in these patients.
Sera
Serum was kept at 41C for a maximum of 24h until transfer to a
 801C freezer. The serum samples were then transferred to the
coordinating centre in dry ice, and stored at –801C. At a later date,
they were sent again in dry ice to a central facility in Italy for
determination of the concentrations of the various parameters. The
mean duration of storage at –801C was 1 year and 9 months, and
ranged from 7 months to 2 years and 9 months.
Measurement of gastric enzymes and hormone
After thawing, sera were assayed blindly. PGA, PGC, and gastrin
were measured by radioimmunoassays (Sorin Biomedica, Saluggia,
Italy) (Plebani et al, 1996). The interassay coefficient of variation
(CV) ranged from 7.4 to 9.5% for PGA levels between 20 and
120mgl
 1, from 5.2 to 8.3% for PGC levels between 2.0 and
50mgl
 1, and from 5.5 to 9.5% for gastrin levels between 40 and
250ngl
 1.
Serological testing for H. pylori and CagA
Anti-H. pylori antibodies were detected by enzyme immunoassays
(EIA): Pyloriset EIA-G test (Orion Diagnostica, Espoo, Finland)
(Granberg et al, 1993); and by immunoblotting using Chiron RIBA
H. pylori SIA (Chiron Diagnostics, Emeryville, CA, USA) (Yamaoka
et al, 1998). Anti-CagA antibodies were detected by immunoblot-
ting using Chiron RIBA H. pylori SIA, an in-house immunoblotting
method performed in one of the centralised facilities (Figura et al,
1998), and by a modified in-house enzyme-linked immunosorbant
assay (ELISA) (Heikkinen et al, 1997).
To be classified positive for H. pylori infection, concordant
results of the Pyloriset EIA-G test and the Chiron RIBA H. pylori
SIA were required. If they were in disagreement, the result of
serology was considered to be undetermined. A similar approach
was applied to the CagA status based on the result of the three
tests. The first two tests performed were the Pyloriset EIA-G test
and the in-house anti-CagA antibodies ELISA and, in case of
disagreement, the Chiron RIBA H. pylori SIA was then carried
out.
Culture of H. pylori
Biopsies obtained from the antrum and the corpus were cultured
locally according to a common protocol (Me ´graud et al, 1999).
Briefly, biopsies were ground with an electric tissue homogeniser
(Ultraturax, LaboModerne, Paris, France) before inoculation onto
a selective medium made of Wilkins Chalgren agar (Oxoid,
Basingstoke, Hampshire, England, UK) enriched with 10% human
blood and rendered selective by the addition of the antibiotics
vancomycin (10mgl
 1), cefsulodin (5mgl
 1), trimethoprim
(5mgl
 1), and cycloheximide (100mgl
 1). The plates were
incubated under microaerobic conditions at 371C for up to 12
days. The organisms were identified as H. pylori by Gram staining,
and urease, oxidase, and catalase activity.
451 patients included in Eurohepygast 
381 patients PGA, PGC
and gastrin
284 patients included in the
present analysis
Patients without gastric hormone values
n = 70
Patients lacking histological diagnosis
n = 97
Figure 1 Patients included in the Eurohepygast study and reasons for
exclusion of the present study.
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Patients were considered to be infected with H. pylori if one of the
three tests was positive: culture, serology, or histology. Patients
were considered to be noninfected when two of the three tests were
negative, and the result of the third was either negative,
undetermined, or missing.
Data analysis
All statistical analyses were performed employing the STATA 5.0
software (Stata Corporation, College Station, TX, USA). Instead of
considering only PGA and PGC alone, the PGA/PGC ratio was
used. PGA and PGA/PGC had normal distributions but, since the
distributions of PGC and gastrin were skewed on the right, a log
transformation was used when the assumption of normality was
needed. The means of these variables were compared between two
groups by Student’s t-tests (PGA and PGA/PGC ratio) or Mann–
Whitney tests (PGC and gastrin); and comparisons between more
than two groups were made with ANOVA (PGA and PGA/PGC
ratio) or Kruskal–Wallis (PGC and gastrin) (Altman, 1991a).
Correlation coefficients between two continuous variables were
calculated as recommended by Altman (1991b).
The evaluation of the performance of gastric hormone
concentrations as biomarkers for ACG was performed using
histological diagnosis as the gold standard. The cut-off point for
each of the biomarkers was determined by means of a receiving
operating characteristic (ROC) curve. It was defined as the best
point able to discriminate between the different histological
patterns of patients with ACG and with normal mucosa or non-
ACG (Altman, 1991c).
The area under the ROC curve measured the discriminatory
ability of the model. General rules for the interpretation of the
value of this area were applied (Hosmer and Lemeshow, 2000). For
areas less than 0.7 the model did not discriminate; for areas 0.7,
0.8, and 0.9 the discrimination was acceptable, excellent, and
outstanding, respectively. The cut-off value of each test was used to
calculate the sensitivity, specificity, positive predictive value
(PPV), negative predictive value (NPV), and accuracy of the test;
95% confidence intervals were calculated subsequently.
Different variables influencing the values of the biomarkers were
identified with multivariate linear regressions adjusted by
histological diagnosis. All variables with Po0.25 in univariate
analyses were included in the complete multivariate linear model.
Multivariate linear regressions were then performed using a
backward elimination procedure (P40.05). The performances of
the biomarkers were then recalculated after adjustment by the
remaining variables of the final linear model.
Variables in the database
The 34 variables used in the univariate analyses were classified into
five groups. The first group included all variables related to
sociodemographic factors, namely, country of residence, country
of birth, socioeconomical status, composition of family, profes-
sion, and level of education. The second group included variables
related to behaviour: smoking habits (non-, ex-, or current
smoker); consumption of alcohol (everyday, occasionally, or
weekend only), sleeping tablets, and tranquillisers; and anxiety
score (Covi et al, 1979). The third group corresponded to host-
related variables, including body mass index (BMI), blood
pressure, ABO and rhesus blood group, family history of digestive
disease, and history of present disease. The fourth group
comprised variables linked to diet. The fifth group was divided
into three strata: H. pylori-negative patients, H. pylori-infected and
CagA-negative patients, and H. pylori-infected and CagA-positive
patients.
Ethics
The study protocol was approved by the local Ethics Committee of
each participating hospital. At inclusion into the study, each
patient was required to sign an informed consent form.
RESULTS
Description of each biomarker
PGA, PGC, PGA/PGC, and gastrin values were available from 381
of the 451 patients included in the study. The mean age of these
381 patients was 43.5 years (s.d.¼13.4 years), and ranged from 19
to 75 years. There were 138 (36.2%) men. In all, 115 (30.2%) of the
patients were born in Western Europe and 249 (65.3%) in Eastern
Europe. Concerning H. pylori status, 37 (10.0%) of the patients
were not infected, 102 (27.7%) were infected but without anti-CagA
antibodies, and 229 (62.2%) were infected and had anti-CagA
antibodies. For 13 patients, the CagA status was unknown. The
histology of 42 patients showed a normal mucosa, of 180 non-ACG,
and of 62 ACG. Among the latter group, 28 patients had antral
predominant atrophy, 27 H. pylori-related corpus-predominant
atrophy, and seven multifocal ACG. In 97 patients, the histological
diagnosis could not be performed properly.
The mean (s.d.) of PGA, PGC, PGA/PGC, and gastrin in the
sample (n¼381) was 77.4mgl
 1 (41.2), 13.2mgl
 1 (9.0), 6.7 (2.6),
and 62.4ngl
 1 (25.3), respectively. PGA and PGC were highly
correlated, with a correlation coefficient of 0.75 (Figure 2). Neither
PGA nor gastrin was correlated to age (correlation coefficient: 0.05
and 0.10, respectively), but PGC increased with age (correlation
coefficient: 0.23) and PGA/PGC decreased with age (correlation
coefficient: –0.24).
The mean values for each of the biomarkers, PGA, PGC, PGA/
PGC, and gastrin, differed significatively according to H. pylori and
CagA status of the patients (P¼0.02, 0.001, o0.0001, and 0.001,
respectively) (Table 1). Interestingly, except for PGC (P¼0.015),
there were no significant differences in the mean values of PGA,
PGA/PGC, and gastrin levels between H. pylori-negative, H. pylori-
positive, and CagA-negative patients (P¼0.45, 0.14, and 0.12,
respectively). However, there was an increase in the PGA mean
value between H. pylori-positive and CagA-negative patients and
H. pylori-positive and CagA-positive patients, which was even
more accentuated for PGC and resulted in a significant decrease in
the PGA/PGC ratio (P¼0.03, o10
 3, and o10
 3, respectively).
The mean values of PGA, PGC, and gastrin increased with the
severity of the atrophy, while they decreased for PGA/PGC (Table 1,
Figure 3). The differences between mean values corresponding to
each histological diagnosis were significant for PGA/PGC, PGC,
and gastrin (Po10
 3 for each of these biomarkers), but not for
PGA (P¼0.28) (Table 1). Interestingly, it was possible to
differentiate three histological groups according to the values of
their PGA/PGC mean: 47 for normal and inflammatory mucosa;
o5 for corpus and multifocal atrophy; and an intermediate value
between the previous two for antral atrophy (Table 1).
Determination of the best threshold for each of the
markers by means of the ROC curve
The results of the ROC curves to discriminate between patients
with ACG and patients with normal mucosa or non-ACG are based
on the sample of 284 patients for whom histological diagnoses
were available (Figure 4). The areas under the ROC curves
determined for PGA, PGC, PGA/PGC, and gastrin were 0.55, 0.62,
0.73, and 0.58, respectively, indicating that the PGA/PGC ratio was
the only potential candidate as a useful biomarker for screening
ACG in this population. The best PGA/PGC cut-off point for
predicting ACG was 5.6. The corresponding validity parameters
were: sensitivity, 65% (95% CI: 52.7, 76.1); specificity, 77.9% (95%
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yCI: 72.1, 82.9); PPV, 45.1% (95% CI: 35.1, 55.3); and NPV, 88.9%
(95% CI: 83.9, 92.7). The accuracy of the PGA/PGC ratio as a
diagnostic test was 75%.
The same procedure was applied to discriminate between
patients with H. pylori-related corpus-predominant or multifocal
atrophy and patients with normal, non-ACG, or antral atrophic
mucosa. The areas under the ROC curves determined for PGA,
PGC, PGA/PGC, and gastrin were 0.57, 0.67, 0.84, and 0.69,
respectively (Figure 5). Again, they indicated that the PGA/PGC
ratio was the only potential biomarker for screening H. pylori-
related corpus-predominant or multifocal atrophy in this
population. The best PGA/PGC cut-off point for predicting
H. pylori-related corpus-predominant or multifocal atrophy
was 4.7. The corresponding validity parameters were: sensitivity,
77.1% (95% CI: 61.2, 88.8); specificity, 87.4% (95% CI: 82.9, 91.1);
PPV, 45.8% (95% CI: 33.4, 58.5); and NPV, 96.5% (95% CI: 93.5,
98.4). The accuracy of the PGA/PGC ratio as a diagnostic test
was 86.2%.
Determination of independent variables explaining the
variation of biomarkers by means of a multivariable
linear regression
A multivariable linear regression considering the PGA/PGC ratio
as the outcome, was performed using all 34 variables available in
the database. In the final linear model performed on the sample,
few variables remained associated with a variation of PGA/PGC:
presence of ACG, and presence of H. pylori and CagA antibodies.
In this model, an interaction between age and gender was found,
demonstrating a different age effect on the variation of PGA/PGC
according to gender (Figure 6). The PGA/PGC ratio decreased in
women older than 41 years and in men older than 61 years.
0
50
100
150
200
250
300
350
0 50 100 150 200 250 300 350
r*=0.75
r * : correlation coefficient      PGA (gl−1)
P
G
C
 
(

g
l
−
1
)
Figure 2 Plot of the serum values of pepsinogen (PG) A and PGC in 451 dyspeptic patients. Results of the Eurohepygast study. Coefficient
correlation¼0.75.
Table 1 Mean and standard deviation (s.d.) of pepsinogen (PG) A, PGC, and PGA/PGC ratio in the global sample and according to histological diagnosis
in European dyspeptic patients. Results of the Eurohepygast study
n PGA (lgl
 1) (s.d.)
a PGC (lgl
 1) (s.d.)
a PGA/PGC (s.d.)
a Gastrin (ngl
 1) (s.d.)
a
Global sample 381 77.4 (41.2) 13.2 (9.0) 6.7 (2.6) 62.4 (25.3)
Range 5–320 1.6–60 1.2–17.2 34–262
H. pylori status
b
H. pylori  37 66.1 (31.4) 8.45 (5.6) 8.4 (2.5) 52.9 (101)
H. pylori+CagA  102 70.6 (31.4) 9.9 (4.7) 7.6 (2.6) 61.2 (23.6)
H. pylori+CagA+ 229 80.9 (42.9) 15.5 (10.1) 5.9 (2.3) 64.7 (27.8)
P
c 0.02 0.001 o0.0001 0.001
Histological diagnosis
d
Normal 42 70.4 (33.8) 8.7 (5.2) 8.4 (1.9) 53.7 (12.9)
NACG
e 180 80.3 (40.2) 12.5 (7.3) 7.1 (2.4) 60.9 (18.6)
Antral atrophy 28 77.9 (36.2) 14.5 (11.3) 6.5 (2.3) 55.0 (13.2)
Corpus atrophy 27 70.1 (36.8) 17.2 (11.0) 4.5 (2.1) 73.9 (29.3)
Multifocal atrophy 7 57.9 (43.0) 16.7 (9.7) 3.6 (2.0) 85.7 (47.6)
P
c 0.28 0.0001 o0.0001 0.0002
aStandard deviation;
b13 missing data on H. pylori status;
cP value of ANOVA for PGA and the PGA/PGC ratio or Kruskal–Wallis test for PGC and gastrin;
d97 missing data on
histological diagnosis;
enonatrophic chronic gastritis. Note: the difference in denominator between Tables 1 and 3 is because of five missing data on gastrin measurement for five
patients.
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for women and one for men. In the model for women, the variable
age was divided into two groups, younger than 41, and 41 years old
or older; similarly, in the model for men, the variable age was
divided into younger than 61, and 61 years old or older. In the
model for women, in addition to the difference arising from age
(coefficient¼ –1.35, P¼0.001) for the older group compared to
the younger group, H. pylori-positive and CagA-positive patients
were more likely to have a lower PGA/PGC ratio (coefficient¼
–2.3, P¼0.02) than H. pylori-positive CagA-negative patients
(coefficient¼ 1.1, P¼0.28) compared to H. pylori-negative
patients (Table 2). In the model for men, no variables remained
associated with the variation of PGA/PGC after adjustment by
histological diagnoses. Concerning the results of PGA as an
outcome in the multivariate linear model, only the variable linked
to H. pylori and CagA status remained in the final model. The same
results were observed for PGC. For gastrin, none of the variables
evaluated remained significantly associated.
Attempts to improve the performance of the PGA/PGC
ratio for ACG
According to the results above, in order to discriminate between
patients with ACG and patients with normal mucosa or non-ACG,
a new cut-off point was determined by means of ROC curves
drawn for each of the following three subgroups: men and women
less than 41 years of age, and women 41 years of age or older. For
each of the subgroups, the area under the ROC curve was 0.75,
0.76, and 0.68, respectively (Table 3). The cut-off point determined
for each group was 5.6, 6.4, and 5.6, respectively. Dividing the
sample into H. pylori-negative patients, H. pylori-positive and
CagA-negative patients, and H. pylori-positive and CagA-positive
patients did not improve the performance of the PGA/PGC ratio
when compared to the performance in the total sample.
H. pylori and CagA status did not improve the performances of
PGA and PGC after adjustment by the remaining variables from
the multivariate linear model. This analysis was not carried out for
H. pylori-related corpus-predominant or multifocal atrophy,
because the subsamples were too small.
From the present results, two independent procedures may be
proposed, which require further evaluation (Figure 7). The use of
either procedure in a given population would depend on the type
of atrophy that is being screened: ACG or H. pylori-related corpus/
multifocal atrophy.
DISCUSSION
The main finding of the present study was that the PGA/PGC ratio
is an acceptable marker to screen for ACG, and a good marker for
H. pylori-related corpus-predominant or multifocal atrophy. PGA,
PGC, and gastrin alone were not appropriate as markers for either
condition.
Interestingly, although PGC is secreted from different sites in
the stomach, while PGA increases rapidly, PGC varies slightly, and
Figure 2 indicates that PGC is a mathematical function of PGA.
This relation may explain why the PGA/PGC ratio reflected
stomach ACG more precisely than PGA alone. Therefore, although
the PGA level theoretically reflects corpus atrophy; in this study, it
was not a sufficiently good marker either for ACG or for H. pylori-
PGA/PGC
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Figure 3 Distribution of the values of the PGA/PGC ratio according to histological diagnosis in dyspeptic patients. Results of the Eurohepygast study.
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Figure 4 Unadjusted ROC curves of pepsinogen (PG) A, PGC, PGA/
PGC, and gastrin to discriminate between patients with atrophic chronic
gastritis (antral, corpus, or multifocal) and patients with normal or
inflammatory gastric mucosa. Results of the Eurohepygast study.
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reported by Plebani et al (1996) in a study carried out in Italy.
Also, Knight et al (1996) found that the PGA levels alone were not
reliable markers for diagnosis of corpus atrophy in a population of
male workers at high risk of gastric adenocarcinoma.
However, in the Eurogast study, Webb et al (1994) showed that
the prevalence of low PGA levels was greater in countries with high
incidence rates of gastric adenocarcinoma than in countries with
lower rates.
The ability of PGA/PGC to discriminate between patients with
ACG and patients with normal or inflammatory gastric mucosa
was not as good as that found in studies which discriminated
between severe atrophy of the corpus and normal mucosa alone
(Borch et al, 1989). Indeed, the sample in the present study
included patients with a wide range of histological manifestations.
However, because of the differences in study design, in popula-
tions studied and in the definition of histological patterns, the
comparison between the validity of the biomarkers has to be
carried out cautiously.
A limitation of this analysis comes from the sample itself: (i)
Because the sample is comprised of European patients consulting
for dyspepsia in the Gastroenterology Department of teaching
hospitals. (ii) Because all of these patients needed endoscopy,
which selected patients with more severe symptoms. Therefore, it
may not represent the global population of dyspeptic patients who
may have a different prevalence of ACG. Indeed, it is impossible to
obtain biopsies from a random sample of dyspeptic patients, that
include those who are not referred to endoscopy as well as those
who do not enter the health-care system. (iii) Histological
diagnosis was available in 75% of these endoscoped patients, but
there were no major differences between the original sample and
the one analysed, thus allowing one to infer the results to the global
sample of patients. Despite these limitations, three aspects of the
methodology make this sample particularly valuable: (i) The best
gold standard available, which is the review of slides by the same
expert pathologist, was used. (ii) A large sample of endoscoped
patients was included. (iii) The wealth of data available from the
included patients allowed the analysis of many factors, which
could influence the results of the biomarkers under study. Thus,
these results can be applied without further validation to the
consulting dyspeptic population referred to gastroscopy or high-
risk populations for gastric cancer in Europe.
Eventual differences in the prevalence of ACG among countries
could result from an inclusion bias. For this reason, the country of
origin was taken into account in the univariate analysis. On
average, there was only a small number of ACG cases per country,
and no difference was found among countries (data not shown),
suggesting that the performances of the biomarkers in this sample
and, in particular, their predictive values would not then vary
among countries. However, the predictive values being dependent
on the prevalence, if ACG prevalence was 10%, the NPV would
increase to 95% and the PPV would decrease to 24.7%, and if ACG
prevalence was 5% the NPV would be 97.7% and the PPV 13.4%.
The possible overestimation of H. pylori prevalence owing to
misclassification of infected patients was certainly very small.
Indeed, the three tests – serology, culture, and histology – were in
good agreement: 122 of 156 cases (78.2%), including 104 positive
and 18 negative.
To the best of our knowledge, the effects of serum storage duration
under standard conditions on the accuracy of these hormone tests
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Figure 5 Unadjusted ROC curves of pepsinogen (PG) A, PGC, PGA/
PGC, and gastrin to discriminate between patients with H. pylori-related
corpus predominant or multifocal atrophy only and patients with normal,
inflammatory, or antral atrophic gastric mucosa. Results of the Euro-
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study was therefore compared between false positive/negative and
true positive/negative samples and no differences were found.
Furthermore, there were no major differences in the distribution of
false-positive/-negative samples between the different centres, and the
s t o r a g et i m ew a sc o n s i s t e n tb e t w e e nc e n t r e s .
The decrease in the PGA/PGC ratio for women 41 years or older
was not linked to an increase in the proportion of ACG in this age
Table 2 Multivariable linear regression of PGA/PGC, final model in men and in women. Results of the Eurohepygast study
Men Women
n=115 Coeff.
a 95% Cl
b Pn =162 Coeff.
a 95% Cl
b P
Age
o61 years (men) or 41 years (women) 104 Baseline 63 Baseline
X61 years (men) or 41 years (women) 11  0.89  2.16,  0.38 0.169 99  1.35  2.11,0.60 0.001
H. pylori and CagA status
H. pylori  16 Baseline 13 Baseline
H. pylori+CagA  27 0.88  0.72, 2.49 0.28 44  1.11  3.14,0.92 0.28
H. pylori+CagA+ 72  1.07  2.76,  0.62 o10
 3 105  2.29  4.21, 0.37 0.020
aCoefficient adjusted on histological diagnosis;
b95% confidence interval.
Table 3 Comparison of the performance of PGA/PGC ratio as a diagnostic test to detect histological lesions acccording to gender and age. Results of the
Eurohepygast study
Diagnosis of ACG
a Diagnosis of corpus or multifocal atrophy
Global sample Men Womeno41 years old Women X 41 years old Global sample
n=289 n=117 n=70 n=102 n=289
Area under ROC curve 0.73 0.75 0.76 0.68 0.84
Cut-off point 5.6 5.6 6.4 5.6 4.7
Sensitivity (%) 65.1 64 75 69.2 77.1
95% CI
b 52.7, 76.1 44.1, 80.8 45.9, 93.2 49.8, 84.6 61.2, 88.8
Specificity (%) 77.9 84.8 70.7 65.8 87.4
95% CI
b 72.1, 82.9 76.3, 91.1 58.1, 81.3 54.6, 75.8 82.9, 91.1
PPV
c (%) 45.1 53.3 34.6 40.9 45.8
95% CI
b 35.1, 55.3 35.6, 70.5 18.4, 54.1 27.2, 55.8 33.4, 58.5
NPV
d (%) 88.9 89.6 93.2 86.2 96.5
95% CI
b 83.9, 92.7 81.9, 94.8 82.6, 98.2 75.5, 93.4 93.5, 98.4
Accuracy (%) 75.1 80 71.4 66.7 86.2
aAtrophic chronic gastritis;
b95% confidence interval;
cpositive predictive value;
dnegative predictive value.
A 
Dyspeptic 
patients
Women < 41 years old
Women >  > 41 years old 
or men
B
Dyspeptic 
patients
PGA/PGC < 4.7
PGA/PGC > 4.7  
Normal, 
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multifocal
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PGA/PGC < 5.6
93.2%
88.3%
45.9%
34.6%
45.8%
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Proportion of patients 
correctly diagnosed
*NACG- nonatrophic chronic gastritis, **ACG- atrophic chronic gastritis
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Figure 7 Proposed procedures and cut-off points of the PGA/PGC ratio to screen for gastric atrophy. Results of the Eurohepygast study: (A) to diagnose
atrophic chronic gastritis (antral, corpus, or multifocal); (B) to diagnose H. pylori-related corpus-predominant or multifocal atrophy only.
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for men and women (data not shown). Furthermore, after
adjusting the two multivariate linear models (for men and women)
by histological diagnosis, the relation between age and PGA/PGC
disappeared in men, but not in women. It seems that in women
aged 41 years or older, factors other than the presence of ACG may
influence the variation of the PGA/PGC ratio. In the Eurogast
study, Webb et al (1994) also found that the PGA level was lower in
women and decreased with age. The role of female hormones may
be worth investigating in this context. Among the other factors
studied, the effect of CagA status in H. pylori-infected patients on
the variation of PGA/PGC has been previously described (Kuipers
et al, 1995; Webb et al, 1999).
In the context of epidemiological studies or clinical trials in
which a large number of individuals or patients must be followed
up or tested, a noninvasive, reliable test is of the utmost
importance to improve the compliance of the subjects in the
study, to minimise as much as possible the loss of data, to follow-
up. The results presented here are an important starting point for
(1) the validation in other independent samples of these threshold
values determined for PGA/PGC, and the proposed procedures to
discriminate among different histological entities; and (2) the
analysis of the natural history of atrophy in these Eurohepygast
patients for whom a 3-year follow-up has been carried out.
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